[Study on the relationship of platelet specific-autoantibodies with therapeutic outcomes by dexamethasone in immune thrombocytopenia purpura].
[Study on the relationship of platelet specific-autoantibodies with therapeutic outcomes by dexamethasone in immune thrombocytopenia purpura].
复制标题
DOI：
10.3760/cma.j.issn.0253-2727.2015.03.006
复制
发表时间：
2015-03-01
影响因子：
--
通讯作者：
Zeng, Qingshu
中科院分区：
文献类型：
--
作者：
Chen, Yang;Ge, Jian;Zeng, Qingshu
目的：目的：探讨地塞米松对不同类型血小板特异性自身抗体阳性的成人免疫性血小板减少性紫癜（ITP）的疗效差异。所有患者均接受地塞米松治疗，起始剂量40 mg/d，连用4 d，小剂量5-10 mg/d，连用3-4周。结果：在IgG阳性患者中，抗GPIIb/IIIa抗体、抗GPIb α抗体、双抗体阳性和双抗体阴性的应答率分别为87.5%、50.0%、68.0%和72.3%（χ 2 =11.489，P
OBJECTIVE: To investigate the different outcomes by dexamethasone in adults immune thrombocytopenia purpura (ITP) with different types of platelet specific-autoantibodies.METHODS: A total of 185 ITP were enrolled, 61 males and 124 females, with a median age of 42 (18-83) years, including 117 newly diagnosed, 35 persistent, and 33 chronic cases. All the patients received the dexamethasone at an initial dose of 40 mg per day for 4 days and a low dose of 5-10 mg for 3-4 weeks. The platelet specific-autoantibodies were identified by the modified monoclonal antibody-specific immobilization of platelet antigen (MAIPA) assay.RESULTS: Among the IgG positive patients, the response rates in anti-GPIIb/IIIa antibody, anti-GPIbalpha antibody, both antibody positive, and both antibody negative were 87.5%, 50.0%, 68.0%, and 72.3% (chi=11.489, P